Monitoring of minimal residual disease using WT1 assay for patients with chronic myeloid leukemia who undergo allogeneic stem cell transplantation [1]

Bone Marrow Transplantation

Volumn 34, Issue 7, 2004, Pages 653-654

  Tamaki, H ^a,b   Ogawa, H ^a  

^a OSAKA UNIVERSITY   (Japan)

^b MINAMI OSAKA GENERAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; WT1 PROTEIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD SAMPLING; CANCER RECURRENCE; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CORRELATION ANALYSIS; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LETTER; LEUKEMIA CELL LINE; LEUKEMOGENESIS; MINIMAL RESIDUAL DISEASE; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; TUMOR DIFFERENTIATION;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; NEOPLASM, RESIDUAL; TRANSPLANTATION, HOMOLOGOUS; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 5044245850     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704620     Document Type: Letter

References (10)

1. Inoue K, Sugiyama H, Ogawa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071-3079.
2. Uzunel M, Ringden O. Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 33: 47-52.
3. Phelan SA, Lindberg C, Call KM. Wilms' tumor gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells. Cell Growth Differ 1994; 5: 677-686.
4. Shtivelman E, Gale RP, Dreazen O et al. bcr-abl RNA in patients with chronic myelogenous leukemia. Blood 1987; 69: 971-973.
5. Cilloni D, Saglio G. Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy. Semin Hematol 2003; 40(Suppl. 2): 37-41.
6. Inoue K, Ogawa H, Yamagami et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996; 88: 2267-2278.
7. Ogawa H, Tamaki H, Ikegame K et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101: 1698-1704.
8. Tamaki H, Mishima M, Kawakami M et al. Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1). Int J Hematol 2003; 78: 349-356.
9. Inoue K, Tamaki H, Ogawa H et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998; 91: 2969-2976.
10. Tamaki H, Ogawa H, Inoue K et al. Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia. Blood 1996; 88: 4396-4398.